Capula Management Ltd Takes Position in Penumbra, Inc. $PEN

Capula Management Ltd purchased a new position in Penumbra, Inc. (NYSE:PEN) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 101,779 shares of the company’s stock, valued at approximately $33,421,000. Penumbra comprises approximately 0.2% of Capula Management Ltd’s portfolio, making the stock its 15th biggest position.

A number of other hedge funds have also recently bought and sold shares of the business. Royal Bank of Canada boosted its stake in shares of Penumbra by 35.8% during the 1st quarter. Royal Bank of Canada now owns 19,332 shares of the company’s stock valued at $5,169,000 after buying an additional 5,092 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Penumbra by 209.1% in the second quarter. EverSource Wealth Advisors LLC now owns 272 shares of the company’s stock valued at $70,000 after acquiring an additional 184 shares in the last quarter. Cerity Partners LLC boosted its stake in Penumbra by 22.3% during the 2nd quarter. Cerity Partners LLC now owns 10,030 shares of the company’s stock valued at $2,574,000 after acquiring an additional 1,829 shares during the last quarter. California Public Employees Retirement System boosted its stake in Penumbra by 7.9% during the 2nd quarter. California Public Employees Retirement System now owns 61,027 shares of the company’s stock valued at $15,661,000 after acquiring an additional 4,491 shares during the last quarter. Finally, Daiwa Securities Group Inc. acquired a new position in Penumbra during the 2nd quarter worth $1,137,000. Institutional investors and hedge funds own 88.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on PEN shares. Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a research note on Friday, July 17th. Zacks Research downgraded shares of Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Wall Street Zen upgraded shares of Penumbra to a “hold” rating in a research note on Saturday, May 9th. Evercore reaffirmed an “outperform” rating and issued a $320.00 price target on shares of Penumbra in a report on Monday, July 6th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $374.00 target price on shares of Penumbra in a report on Thursday, June 11th. Three investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Penumbra presently has an average rating of “Hold” and an average price target of $360.33.

Penumbra Stock Performance

Shares of PEN stock opened at $317.83 on Friday. The business has a 50 day simple moving average of $319.53 and a 200 day simple moving average of $330.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95. The firm has a market capitalization of $12.50 billion, a price-to-earnings ratio of 73.23, a price-to-earnings-growth ratio of 1.96 and a beta of 0.70. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $362.41.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). The business had revenue of $374.76 million for the quarter, compared to analyst estimates of $370.47 million. Penumbra had a net margin of 11.76% and a return on equity of 10.87%. Penumbra’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same period last year, the business posted $0.83 earnings per share. On average, equities research analysts anticipate that Penumbra, Inc. will post 5.02 EPS for the current year.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.